Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ERN1 | O75460 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5734347 | 0.86 | VCAM1 (0.68) | VCAM1HPGDALDH1A1NPSR1LMNA | |
| SCHEMBL30863327 | 0.85 | VCAM1 (0.66) | VCAM1HPGDALDH1A1NPSR1LMNA | |
| SCHEMBL531728 | 0.83 | VCAM1 (0.64) | VCAM1HPGDALDH1A1NPSR1LMNA | |
| SCHEMBL30525281 | 0.83 | VCAM1 (0.64) | VCAM1HPGDALDH1A1NPSR1LMNA | |
| SCHEMBL193275 | 0.83 | TSHR (0.68) | VCAM1HPGDALDH1A1NPSR1LMNA | |
| SCHEMBL30443852 | 0.83 | TSHR (0.68) | VCAM1HPGDALDH1A1NPSR1LMNA | |
| SCHEMBL559830 | 0.83 | VCAM1 (0.64) | VCAM1HPGDALDH1A1NPSR1LMNA | |
| SCHEMBL31493 | 0.82 | VCAM1 (0.62) | VCAM1HPGDALDH1A1NPSR1LMNA | |
| SCHEMBL7566531 | 0.82 | ALDH1A1 (0.65) | VCAM1HPGDALDH1A1NPSR1LMNA | |
| SCHEMBL11378677 | 0.82 | VCAM1 (0.62) | VCAM1HPGDALDH1A1NPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9234225-B2 | Method for generating human milk oligosaccharides (HMOs) or precursors thereof | GLYCOM A/S (DK) | 2016-01-12 | — | — | US | disclosed |
| US-20150182549-A1 | METHOD FOR ENZYMATIC GLYCOSYLATION OF OLIGOSACCHARIDES FROM MAMMALIAN ANIMAL MILK | GLYCOM A/S (DK) | 2015-07-02 | — | — | US | disclosed |
| US-20150183816-A1 | MODIFIED GALACTOOLIGOSACCHARIDES | GLYCOM A/S (DK) | 2015-07-02 | — | — | US | disclosed |
| EP-2864492-A1 | MODIFIED GALACTOOLIGOSACCHARIDES | Glycom A/S (DK) | 2015-04-29 | — | — | EP | disclosed |
| EP-2864344-A1 | METHOD FOR ENZYMATIC GLYCOSYLATION OF OLIGOSACCHARIDES FROM MAMMALIAN ANIMAL MILK | Glycom A/S (DK) | 2015-04-29 | — | — | EP | disclosed |
| US-20140234912-A1 | METHOD FOR GENERATING HUMAN MILK OLIGOSACCHARIDES (HMOs) OR PRECURSORS THEREOF | GLYCOM A/S (DK) | 2014-08-21 | — | — | US | disclosed |
| EP-2707493-A1 | METHOD FOR GENERATING HUMAN MILK OLIGOSACCHARIDES (HMOs) OR PRECURSORS THEREOF | Glycom A/S (DK) | 2014-03-19 | — | — | EP | disclosed |
| WO-2013190529-A1 | GLYCOSYLATED GALACTOSYL DISACCHARDDES, METHODS FOR THEIR PRODUCTION AND THEIR USE IN CONSUMABLE PRODUCTS | GLYCOM A/S (DK) | 2013-12-27 | — | — | WO | disclosed |
| WO-2013190530-A1 | MODIFIED GALACTOOLIGOSACCHARIDES | GLYCOM A/S (DK) | 2013-12-27 | — | — | WO | disclosed |
| WO-2013190531-A1 | GLYCOSYLATED GALACTOSYL DISACCHARIDES, METHODS FOR THEIR PRODUCTION AND THEIR USE IN CONSUMABLE PRODUCTS | GLYCOM A/S (DK) | 2013-12-27 | — | — | WO | disclosed |
| WO-2012156897-A1 | METHOD FOR GENERATING HUMAN MILK OLIGOSACCHARIDES (HMOs) OR PRECURSORS THEREOF | GLYCOM A/S (DK) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182549-A1 | METHOD FOR ENZYMATIC GLYCOSYLATION OF OLIGOSACCHARIDES FROM MAMMALIAN ANIMAL MILK | GALE, SI, FUT6 | VCAM1 3437/4885HPGD 835/4885ALDH1A1 786/4885 |
| US-20150183816-A1 | MODIFIED GALACTOOLIGOSACCHARIDES | FUT6, GALE, FUT5 | VCAM1 1817/4885HPGD 1628/4885ALDH1A1 1176/4885 |
| US-20140234912-A1 | METHOD FOR GENERATING HUMAN MILK OLIGOSACCHARIDES (HMOs) OR PRECURSORS THEREOF | LCT, B4GALT1, GALNT1 | VCAM1 4061/4885HPGD 373/4885ALDH1A1 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.